Carbon Biosciences
- Company typePrivate
- Founded2021
- HeadquartersLexington, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Carbon Biosciences firmographics
Firmographics- Name
- Carbon Biosciences
- Legal name
- Carbon Biosciences
- Website
- https://carbonbio.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Carbon Biosciences industry classification
Industry- Product category
- Gene Therapy / Biopharmaceuticals
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- AAV Vector Gene Therapy Developers (HLAAACAA)
- akta.pro secondary industry
- mRNA Therapeutics (vaccines, protein replacement, immuno-oncology) (HLAAADAA)
Keywords
Where Carbon Biosciences is headquartered
LocationHeadquarters
- HQ city
- Lexington
- HQ country
- United States
- HQ region
- North America
Markets served
Carbon Biosciences business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
Carbon Biosciences product offering
Product offeringCore offering
Carbon Biosciences develops a novel parvovirus-based gene therapy platform combined with circular RNA technology for the treatment of genetic diseases with high unmet medical needs, with an initial focus on cystic fibrosis. The platform emphasizes tissue-specific delivery and the ability to re-administer therapies, addressing a key limitation of conventional gene therapies for chronic genetic conditions.
Product overview
Carbon Biosciences is a biotechnology company developing two complementary technology platforms: a circular RNA technology platform for therapies and vaccines, and a novel parvovirus-based gene therapy platform for genetic diseases. The company focuses on advancing treatments for genetic diseases such as cystic fibrosis using these proprietary platform technologies.
Differentiator
Problem solved
Functional benefit
Companies that use Carbon Biosciences
Customer profileSegments1 record
Ideal customer profiles2 records
Carbon Biosciences technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Carbon Biosciences partnerships and signals
Strategic signalScale indicators2 records
Recent moves5 records
Expansion highlights5 records
Carbon Biosciences competitors and assessment
Company assessmentBroad incumbents
- Sarepta Therapeutics: Commercial-stage leader in genetic medicine for Duchenne and other rare diseases, including AAV-based gene therapies. Broadly comparable as a gene therapy incumbent with established manufacturing, regulatory, and commercial infrastructure.
- Vertex Pharmaceuticals: Commercial leader in cystic fibrosis treatment (Trikafta/Kaftrio) and expanding into genetic therapies via the Alpine Immune Sciences and other acquisitions. The dominant CF incumbent whose standard of care defines the competitive landscape for any CF gene therapy.
Direct peers
- Regenxbio: Clinical-stage AAV gene therapy platform company developing treatments for rare diseases including CF (via RGX-121 in other indications). Most directly comparable as an AAV/parvovirus-based platform developer with rare disease focus.
- uniQure: Clinical-stage gene therapy company developing AAV-based treatments for rare diseases, including CNS and cardiovascular indications. Comparable platform-based approach and rare disease therapeutic focus.
- Solid Biosciences: Gene therapy company developing AAV-based treatments, initially focused on Duchenne muscular dystrophy. Comparable as an early-stage platform developer leveraging AAV for genetic disease with similar capital intensity profile.
- Taysha Gene Therapies: Clinical-stage AAV gene therapy developer focused on monogenic CNS diseases. Comparable as an early-stage platform-driven AAV gene therapy company with similar capital and timeline dynamics.
- Krystal Biotech: Commercial-stage gene therapy company (Vyjuvek) using a delivery platform for rare genetic skin diseases. Comparable as a platform-based gene therapy developer that has successfully commercialized a non-AAV delivery approach for rare disease.
- Passage Bio: Clinical-stage AAV gene therapy developer focused on rare monogenic CNS diseases. Comparable as a similarly-sized platform-driven AAV gene therapy company with preclinical-to-early-clinical stage profile.
Emerging players
- Spirovant Sciences: Gene therapy company developing AAV-based treatments specifically for cystic fibrosis. Highly comparable given shared CF indication focus and AAV delivery approach, making it a direct head-to-head competitor in CF genetic medicine.
- 4D Molecular Therapeutics: Clinical-stage gene therapy company with proprietary AAV capsid engineering for tissue-specific delivery. Comparable given parallel emphasis on tissue-targeted delivery and redosing capability, and active CF program (4D-710).
Market position
Strengths5 records
Weaknesses5 records
Competitive moat2 records
Key risks5 records
Key highlights6 records
Customer concentration
Carbon Biosciences social profiles
Digital presenceCarbon Biosciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
Carbon Biosciences leadership team
Management profileNumber of profiles
Profiles3 records
Carbon Biosciences funding detail
Funding detailFunding overview
Funding rounds1 record
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Carbon Biosciences M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Carbon Biosciences
What does Carbon Biosciences do?
Carbon Biosciences develops a novel parvovirus-based gene therapy platform combined with circular RNA technology for the treatment of genetic diseases with high unmet medical needs, with an initial focus on cystic fibrosis. The platform emphasizes tissue-specific delivery and the ability to re-administer therapies, addressing a key limitation of conventional gene therapies for chronic genetic conditions.
Is Carbon Biosciences a public or private company?
Carbon Biosciences is a private company. It is classified as venture growth investor backed and is currently operating.
When was Carbon Biosciences founded?
Carbon Biosciences was founded in 2021. It employs 11 to 50 people.
Where is Carbon Biosciences based?
Carbon Biosciences is headquartered in Lexington, United States, in the North America region.
Who are Carbon Biosciences's main competitors?
Broad incumbents on record are Sarepta Therapeutics and Vertex Pharmaceuticals. Direct peers are Regenxbio, uniQure, Solid Biosciences, Taysha Gene Therapies, Krystal Biotech and Passage Bio. Emerging players are Spirovant Sciences and 4D Molecular Therapeutics.
Does Carbon Biosciences have an API?
No public API is recorded for Carbon Biosciences.
What industry is Carbon Biosciences in?
Carbon Biosciences's product category is Gene Therapy / Biopharmaceuticals. Its primary akta.pro industry code is HLAAACAA, AAV Vector Gene Therapy Developers, with a secondary code of HLAAADAA, mRNA Therapeutics (vaccines, protein replacement, immuno-oncology). Its NAICS code is 541714 and its SIC code is 2836.